trial · primary record
Denosumab (reduced dosing)
Metastatic Breast Cancer
| Phase | Phase 3 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 1380 |
| Primary completion | 2026-03-20 |
| Primary endpoint | Time to first on-trial symptomatic skeletal event (SSE; Clinically significant pathological fracture, radiation therapy to bone, surgery to bone or spinal cord compression). |
| Registry ID | NCT02051218 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:02.487Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02051218
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.